<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7250768\results\search\disease\results.xml">
  <result pre=": Review Article Cardiovascular comorbidities and complications associated with coronavirus" exact="disease" post="2019 MahajanKunalkunalmahajan442@gmail.comaâˆ—ChandraK.Saratb[a], [b], âˆ—Corresponding author. kunalmahajan442@gmail.com ppub: 2020-7epub: 2020-5-5763253260received:"/>
  <result pre="kunalmahajan442@gmail.com ppub: 2020-7epub: 2020-5-5763253260received: 2020-4-8accepted: 2020-5-6(C) , 2020 Abstract Coronavirus" exact="disease" post="2019 (COVID-19) has caused a devastating global pandemic and"/>
  <result pre="affects the lungs, it shares a strong interplay with the" exact="cardiovascular" post="system. The presence of underlying cardiovascular diseaseÂ and its"/>
  <result pre="strong interplay with the cardiovascular system. The presence of underlying" exact="cardiovascular" post="diseaseÂ and its risk factors (diabetes, hypertension) predispose the"/>
  <result pre="COVID-19. On the other hand, COVID-19 itself leads to various" exact="cardiovascular" post="complications, which increase its associated morbidity and mortality in"/>
  <result pre="data in this field and understand the mechanisms behind the" exact="cardiovascular" post="involvement of this lethal disease. Keywords Coronavirus COVID-19 Cardiovascular"/>
  <result pre="cardiovascular involvement of this lethal disease. Keywords Coronavirus COVID-19 Cardiovascular" exact="disease" post="Complications Comorbidities Introduction The whole world is facing an"/>
  <result pre="facing an unprecedented challenge of stopping a virus called â€œsevere" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)â€� that has caused havoc"/>
  <result pre="an unprecedented challenge of stopping a virus called â€œsevere acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)â€� that has caused havoc affecting"/>
  <result pre="unprecedented challenge of stopping a virus called â€œsevere acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)â€� that has caused havoc affecting more"/>
  <result pre="globe.1 World Health Organization has named the new and lethal" exact="disease" post="caused by SARS-CoV-2 as â€œCOVID-19â€� (Coronavirus Disease 2019).2 Over"/>
  <result pre="new and lethal disease caused by SARS-CoV-2 as â€œCOVID-19â€� (Coronavirus" exact="Disease" post="2019).2 Over a short span of fewer than five"/>
  <result pre="caused by SARS-CoV-2 as â€œCOVID-19â€� (Coronavirus Disease 2019).2 Over a" exact="short" post="span of fewer than five months, COVID-19 has affected"/>
  <result pre="more than 785 deaths as a result of this deadly" exact="viral" post="disease. COVID-19 is primarily a respiratory disease; however, observational"/>
  <result pre="result of this deadly viral disease. COVID-19 is primarily a" exact="respiratory" post="disease; however, observational studies have shown a strong interplay"/>
  <result pre="observational studies have shown a strong interplay between COVID-19 and" exact="cardiovascular disease" post="(CVD).3,4 COVID-19 tends to be more severe in patients"/>
  <result pre="studies have shown a strong interplay between COVID-19 and cardiovascular" exact="disease" post="(CVD).3,4 COVID-19 tends to be more severe in patients"/>
  <result pre="CVD or those with risk factors of CVD such as" exact="diabetes mellitus" post="(DM) and hypertension (HTN).3, 4, 5 Furthermore, it has"/>
  <result pre="risk factors of CVD such as diabetes mellitus (DM) and" exact="hypertension" post="(HTN).3, 4, 5 Furthermore, it has been seen that"/>
  <result pre="to know how to mitigate the risk of this lethal" exact="disease" post="among the most vulnerable of our population. However, for"/>
  <result pre="caused by this novel coronavirus infection. Fig.Â 1 Mechanisms behind" exact="cardiovascular" post="injury associated with COVID-19. SARS-CoV-2 = severe acute respiratory"/>
  <result pre="Mechanisms behind cardiovascular injury associated with COVID-19. SARS-CoV-2 = severe" exact="acute" post="respiratory syndrome coronavirus 2; ARDSÂ =Â acute respiratory distress"/>
  <result pre="behind cardiovascular injury associated with COVID-19. SARS-CoV-2 = severe acute" exact="respiratory" post="syndrome coronavirus 2; ARDSÂ =Â acute respiratory distress syndrome;"/>
  <result pre="cardiovascular injury associated with COVID-19. SARS-CoV-2 = severe acute respiratory" exact="syndrome" post="coronavirus 2; ARDSÂ =Â acute respiratory distress syndrome; ACE-2Â"/>
  <result pre="SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; ARDSÂ =Â" exact="acute" post="respiratory distress syndrome; ACE-2Â =Â angiotensin-converting enzyme-2. Coronaviruses and"/>
  <result pre="= severe acute respiratory syndrome coronavirus 2; ARDSÂ =Â acute" exact="respiratory" post="distress syndrome; ACE-2Â =Â angiotensin-converting enzyme-2. Coronaviruses and mechanism"/>
  <result pre="bats, with Malayan pangolins (who share 91% nucleotide identity) as" exact="intermediate" post="hosts.6 There are seven known human coronaviruses. Four of"/>
  <result pre="of these seven coronaviruses (229E, OC43, NL63, and HKU1) are" exact="benign" post="and cause only self-resolving infections and account for 15â€&quot;30%"/>
  <result pre="OC43, NL63, and HKU1) are benign and cause only self-resolving" exact="infections" post="and account for 15â€&quot;30% of common colds. However, the"/>
  <result pre="in 2002 by SARS-CoV, in 2012 by the Middle East" exact="respiratory" post="syndrome coronavirus (MERS)-CoV, and now COVID-19, a global pandemic"/>
  <result pre="2002 by SARS-CoV, in 2012 by the Middle East respiratory" exact="syndrome" post="coronavirus (MERS)-CoV, and now COVID-19, a global pandemic in"/>
  <result pre="SARS-CoV-2.6 Of all three, COVID-19 appears to have the highest" exact="secondary" post="infection rate (Fig.Â 2). However, mortality seems to be"/>
  <result pre="Of all three, COVID-19 appears to have the highest secondary" exact="infection" post="rate (Fig.Â 2). However, mortality seems to be lowest"/>
  <result pre="associated with cardiac complications, mainly in the form of myocarditis," exact="heart" post="failure, and arrhythmias.6 Fig.Â 2 Epidemiological comparison of respiratory"/>
  <result pre="myocarditis, heart failure, and arrhythmias.6 Fig.Â 2 Epidemiological comparison of" exact="respiratory" post="viral infections. SARS-coronaviruses contain glycosylated spike proteins that bind"/>
  <result pre="heart failure, and arrhythmias.6 Fig.Â 2 Epidemiological comparison of respiratory" exact="viral" post="infections. SARS-coronaviruses contain glycosylated spike proteins that bind to"/>
  <result pre="2 (ACE-2) receptors, after activation by transmembrane protease serine 2.3" exact="Alveolar" post="epithelial cells appear to be the primary portal of"/>
  <result pre="(ACE-2) receptors, after activation by transmembrane protease serine 2.3 Alveolar" exact="epithelial" post="cells appear to be the primary portal of entry"/>
  <result pre="protease serine 2.3 Alveolar epithelial cells appear to be the" exact="primary" post="portal of entry for SARS-CoV-2, explaining its predominantly respiratory"/>
  <result pre="the primary portal of entry for SARS-CoV-2, explaining its predominantly" exact="respiratory" post="symptoms. ACE-2 is expressed mainly by the epithelial cells"/>
  <result pre="its predominantly respiratory symptoms. ACE-2 is expressed mainly by the" exact="epithelial" post="cells of the lungs, heart, intestine, kidney, and blood"/>
  <result pre="angiotensin I to angiotensin II, which then binds to the" exact="type 1" post="angiotensin II receptors. On the other hand, the principal"/>
  <result pre="SARS-CoV-2 binds to the ACE-2 receptor, it, therefore, attenuates the" exact="residual" post="ACE-2 activity, thus leading to a state of inappropriately"/>
  <result pre="lot of adverse effects. Besides inducing local, as well as" exact="systemic" post="HTN and vasoconstriction, Ang-II is proatherosclerotic and causes inflammatory"/>
  <result pre="organ damage. Locally increased Ang-II also triggers an increase in" exact="vascular" post="permeability resulting in pulmonary edema and acute respiratory distress"/>
  <result pre="Ang-II also triggers an increase in vascular permeability resulting in" exact="pulmonary" post="edema and acute respiratory distress syndrome (ARDS)â€&quot;like picture.7,8 Thus,"/>
  <result pre="an increase in vascular permeability resulting in pulmonary edema and" exact="acute" post="respiratory distress syndrome (ARDS)â€&quot;like picture.7,8 Thus, by an effect"/>
  <result pre="increase in vascular permeability resulting in pulmonary edema and acute" exact="respiratory" post="distress syndrome (ARDS)â€&quot;like picture.7,8 Thus, by an effect on"/>
  <result pre="vascular permeability resulting in pulmonary edema and acute respiratory distress" exact="syndrome" post="(ARDS)â€&quot;like picture.7,8 Thus, by an effect on ACE-2 receptors,"/>
  <result pre="Thus, by an effect on ACE-2 receptors, SARS-CoV-2 predisposes to" exact="acute" post="lung injury, myocardial damage, inflammatory organ damage, and a"/>
  <result pre="acute lung injury, myocardial damage, inflammatory organ damage, and a" exact="prothrombotic state," post="responsible for its varied systemic complications and multiorgan dysfunction."/>
  <result pre="organ damage, and a prothrombotic state, responsible for its varied" exact="systemic" post="complications and multiorgan dysfunction. Direct invasion of myocyte by"/>
  <result pre="state, which results in a cytokine storm triggered by an" exact="uncontrolled" post="and dysfunctional immune response by type 1 and type"/>
  <result pre="storm triggered by an uncontrolled and dysfunctional immune response by" exact="type 1" post="and type 2Â T helper cells.7 This results in"/>
  <result pre="637 patients with MERS, the prevalence of DM, HTN, CVD," exact="and obesity" post="was 50%, 50%, 30%, and 16%, respectively.11 Similar trends"/>
  <result pre="patients with MERS, the prevalence of DM, HTN, CVD, and" exact="obesity" post="was 50%, 50%, 30%, and 16%, respectively.11 Similar trends"/>
  <result pre="and 16%, respectively.11 Similar trends of an increased presence of" exact="cardiovascular" post="comorbidities have been observed in patients with COVID-19. In"/>
  <result pre="and inpatient), the prevalence of patients having pre-existing HTN, DM," exact="coronary artery disease" post="(CAD), and cerebrovascular disease was 15%, 7.4%, 2.5%, and"/>
  <result pre="inpatient), the prevalence of patients having pre-existing HTN, DM, coronary" exact="artery disease" post="(CAD), and cerebrovascular disease was 15%, 7.4%, 2.5%, and"/>
  <result pre="the prevalence of patients having pre-existing HTN, DM, coronary artery" exact="disease" post="(CAD), and cerebrovascular disease was 15%, 7.4%, 2.5%, and"/>
  <result pre="patients having pre-existing HTN, DM, coronary artery disease (CAD), and" exact="cerebrovascular disease" post="was 15%, 7.4%, 2.5%, and 1.4%, respectively.12 Among patients"/>
  <result pre="having pre-existing HTN, DM, coronary artery disease (CAD), and cerebrovascular" exact="disease" post="was 15%, 7.4%, 2.5%, and 1.4%, respectively.12 Among patients"/>
  <result pre="CAD (10.6%) were the three most common comorbidities, followed by" exact="cerebrovascular disease" post="(5.3%) and chronic heart failure (4.1%).13 Similarly, in a"/>
  <result pre="(10.6%) were the three most common comorbidities, followed by cerebrovascular" exact="disease" post="(5.3%) and chronic heart failure (4.1%).13 Similarly, in a"/>
  <result pre="three most common comorbidities, followed by cerebrovascular disease (5.3%) and" exact="chronic" post="heart failure (4.1%).13 Similarly, in a systemic meta-analysis of"/>
  <result pre="most common comorbidities, followed by cerebrovascular disease (5.3%) and chronic" exact="heart" post="failure (4.1%).13 Similarly, in a systemic meta-analysis of 6"/>
  <result pre="disease (5.3%) and chronic heart failure (4.1%).13 Similarly, in a" exact="systemic" post="meta-analysis of 6 Chinese studies, involving 1527 patients, the"/>
  <result pre="6 Chinese studies, involving 1527 patients, the proportions of HTN," exact="cardiovascular disease" post="and DM in patients with COVID-19 were 17.1%, 16.4%,"/>
  <result pre="Chinese studies, involving 1527 patients, the proportions of HTN, cardiovascular" exact="disease" post="and DM in patients with COVID-19 were 17.1%, 16.4%,"/>
  <result pre="among the general population.15 Therefore, the prevalence of HTN and" exact="diabetes" post="in people infected with the virus was not higher"/>
  <result pre="died of COVID-19 in Italy, with pre-existing HTN, DM, CAD," exact="atrial fibrillation," post="and cerebrovascular disease recorded in 76%, 35.5%, 30%, 24.5%,"/>
  <result pre="in Italy, with pre-existing HTN, DM, CAD, atrial fibrillation, and" exact="cerebrovascular disease" post="recorded in 76%, 35.5%, 30%, 24.5%, and 9.6%, respectively.16"/>
  <result pre="Italy, with pre-existing HTN, DM, CAD, atrial fibrillation, and cerebrovascular" exact="disease" post="recorded in 76%, 35.5%, 30%, 24.5%, and 9.6%, respectively.16"/>
  <result pre="that the presence of underlying health conditions such as DM," exact="chronic" post="lung disease, and CVD, were associated with a higher"/>
  <result pre="the presence of underlying health conditions such as DM, chronic" exact="lung disease," post="and CVD, were associated with a higher risk of"/>
  <result pre="were associated with a higher risk of developing severe COVID-19â€&quot;associated" exact="disease" post="than persons without these conditions.17 Thus, it is a"/>
  <result pre="and ARBs (Ang-II Receptor Blockers). Fig.Â 3 Pictorial diagram showing" exact="cardiovascular" post="comorbidities and sequelae of COVID-19. COVID-19Â =Â coronavirus disease-2019;"/>
  <result pre="COVID-19Â =Â coronavirus disease-2019; ACE-2Â =Â angiotensin-converting enzyme-2; CAD =" exact="coronary artery disease." post="Cardiovascular sequelae of COVID-19 Data from the MERS, SARS,"/>
  <result pre="=Â coronavirus disease-2019; ACE-2Â =Â angiotensin-converting enzyme-2; CAD = coronary" exact="artery disease." post="Cardiovascular sequelae of COVID-19 Data from the MERS, SARS,"/>
  <result pre="the MERS, SARS, and influenza epidemics provide enough evidence that" exact="viral" post="infections can cause acute and chronic cardiovascular injury.18,19 Acutely,"/>
  <result pre="MERS, SARS, and influenza epidemics provide enough evidence that viral" exact="infections" post="can cause acute and chronic cardiovascular injury.18,19 Acutely, COVID-19"/>
  <result pre="influenza epidemics provide enough evidence that viral infections can cause" exact="acute" post="and chronic cardiovascular injury.18,19 Acutely, COVID-19 has been shown"/>
  <result pre="provide enough evidence that viral infections can cause acute and" exact="chronic" post="cardiovascular injury.18,19 Acutely, COVID-19 has been shown to trigger"/>
  <result pre="enough evidence that viral infections can cause acute and chronic" exact="cardiovascular" post="injury.18,19 Acutely, COVID-19 has been shown to trigger acute"/>
  <result pre="chronic cardiovascular injury.18,19 Acutely, COVID-19 has been shown to trigger" exact="acute" post="coronary syndromes (ACSs), myocarditis, arrhythmias, acute onset heart failure,"/>
  <result pre="been shown to trigger acute coronary syndromes (ACSs), myocarditis, arrhythmias," exact="acute" post="onset heart failure, and venous thromboembolism (VTE) (Fig.Â 3)."/>
  <result pre="to trigger acute coronary syndromes (ACSs), myocarditis, arrhythmias, acute onset" exact="heart" post="failure, and venous thromboembolism (VTE) (Fig.Â 3). The overall"/>
  <result pre="coronary syndromes (ACSs), myocarditis, arrhythmias, acute onset heart failure, and" exact="venous thromboembolism" post="(VTE) (Fig.Â 3). The overall incidence of acute cardiac"/>
  <result pre="and venous thromboembolism (VTE) (Fig.Â 3). The overall incidence of" exact="acute" post="cardiac injury caused by COVID-19 ranges from 7 to"/>
  <result pre="increased metabolic demand in the background of lung injury induced" exact="hypoxia" post="(Fig.Â 1). All these mechanisms have been explained in"/>
  <result pre="exacerbate underlying CVD and may also give rise to new" exact="cardiovascular" post="injuries.20 Evidence is now available, supporting the fact that"/>
  <result pre="now available, supporting the fact that the risk of developing" exact="cardiovascular" post="complications is more among patients who have pre-existing CVD"/>
  <result pre="high-sensitivity cardiac troponin I (hs-TNI) higher than the 99% percentile" exact="upper" post="reference limit. Patients with elevated hs-TNI were elderly, had"/>
  <result pre="study by Guo etÂ al20 showed that 28% of the" exact="total" post="of 187 hospitalized patients with COVID-19Â had evidence of"/>
  <result pre="total of 187 hospitalized patients with COVID-19Â had evidence of" exact="acute" post="myocardial injury in the form of elevated troponin T"/>
  <result pre="higher cardiac troponin I levels in those with severe COVID-19" exact="infection" post="compared with those without (standardized mean difference: 25.6Â ng/L;"/>
  <result pre="there are two patterns of myocardial injury with COVID-19â€&quot;Primary or" exact="secondary" post="myocardial injury. In a retrospective study of 191 patients"/>
  <result pre="These results led us to believe that cardiac insult occurs" exact="secondary" post="to the cytokine storm or secondary hemophagocytic lympho-histiocytosis rather"/>
  <result pre="that cardiac insult occurs secondary to the cytokine storm or" exact="secondary" post="hemophagocytic lympho-histiocytosis rather than an isolated primary myocardial injury.23"/>
  <result pre="cytokine storm or secondary hemophagocytic lympho-histiocytosis rather than an isolated" exact="primary" post="myocardial injury.23 Another implication of this study is that"/>
  <result pre="intensive care. The other pattern of myocardial injury involves the" exact="primary" post="myocardial damage, in which the patients present predominantly with"/>
  <result pre="which the patients present predominantly with cardiac complaints instead of" exact="respiratory" post="symptoms. It can occur secondary to acute myocardial infarction"/>
  <result pre="with cardiac complaints instead of respiratory symptoms. It can occur" exact="secondary" post="to acute myocardial infarction (type 1) in a patient"/>
  <result pre="complaints instead of respiratory symptoms. It can occur secondary to" exact="acute" post="myocardial infarction (type 1) in a patient with COVID-19."/>
  <result pre="instead of respiratory symptoms. It can occur secondary to acute" exact="myocardial infarction" post="(type 1) in a patient with COVID-19. However, it"/>
  <result pre="However, it can also occur as a result of either" exact="viral" post="myocarditis or stress-induced cardiomyopathy. The possibility of the latter"/>
  <result pre="it can also occur as a result of either viral" exact="myocarditis" post="or stress-induced cardiomyopathy. The possibility of the latter two"/>
  <result pre="case reports where patients with COVID-19 have presented primarily with" exact="chest" post="pain, elevated cardiac enzymes, and left ventricular dysfunction on"/>
  <result pre="presented primarily with chest pain, elevated cardiac enzymes, and left" exact="ventricular dysfunction" post="on echocardiography, along with ST-T changes on electrocardiogram, but"/>
  <result pre="recently published case report, an otherwise healthy 53-year-old woman developed" exact="acute" post="myopericarditis with systolic dysfunction confirmed on cardiac magnetic resonance"/>
  <result pre="cough owing to COVID-19. Interestingly she did not show any" exact="respiratory" post="involvement during the clinical course.25 This case confirmed the"/>
  <result pre="the clinical course.25 This case confirmed the direct role of" exact="viral" post="myocarditis in the pathogenesis of COVID-19 associated myocardial injury."/>
  <result pre="clinical course.25 This case confirmed the direct role of viral" exact="myocarditis" post="in the pathogenesis of COVID-19 associated myocardial injury. It"/>
  <result pre="described the pericardial involvement with COVID-19 for the first time." exact="Sporadic" post="autopsy reports in patients with COVID-19 with high viral"/>
  <result pre="time. Sporadic autopsy reports in patients with COVID-19 with high" exact="viral" post="load have suggested infiltration of myocardium by interstitial mononuclear"/>
  <result pre="available, one should have a high index of suspicion for" exact="acute" post="myocarditis if a patient with COVID-19 presents with raised"/>
  <result pre="one should have a high index of suspicion for acute" exact="myocarditis" post="if a patient with COVID-19 presents with raised cardiac"/>
  <result pre="with raised cardiac enzymes, new onset or worsening cardiac arrhythmias," exact="and heart" post="failure. Arrhythmias Cardiac arrhythmias are a common manifestation in"/>
  <result pre="raised cardiac enzymes, new onset or worsening cardiac arrhythmias, and" exact="heart" post="failure. Arrhythmias Cardiac arrhythmias are a common manifestation in"/>
  <result pre="enzymes, new onset or worsening cardiac arrhythmias, and heart failure." exact="Arrhythmias" post="Cardiac arrhythmias are a common manifestation in patients with"/>
  <result pre="new onset or worsening cardiac arrhythmias, and heart failure. Arrhythmias" exact="Cardiac" post="arrhythmias are a common manifestation in patients with COVID-19."/>
  <result pre="not specified. The possible mechanisms behind the higher prevalence of" exact="arrhythmia" post="among patients with COVID-19 include myocardial ischemia/injury, viral infectionâ€&quot;induced"/>
  <result pre="prevalence of arrhythmia among patients with COVID-19 include myocardial ischemia/injury," exact="viral" post="infectionâ€&quot;induced state of hypoxia, fever, metabolic disarray, neurohormonal dysregulation,"/>
  <result pre="The risk of arrhythmias is more in patients with severe/critical" exact="disease" post="and pre-existing CVD/inherited arrhythmia syndromes.28,29 Malignant arrhythmias in the"/>
  <result pre="is more in patients with severe/critical disease and pre-existing CVD/inherited" exact="arrhythmia" post="syndromes.28,29 Malignant arrhythmias in the presence of troponin elevation"/>
  <result pre="in patients with severe/critical disease and pre-existing CVD/inherited arrhythmia syndromes.28,29" exact="Malignant" post="arrhythmias in the presence of troponin elevation should raise"/>
  <result pre="of troponin elevation should raise the suspicion of fulminant myocarditis.3" exact="Arrhythmias" post="in the setting of COVID-19 should be treated in"/>
  <result pre="be treated in the same way as in non-COVID patients.3" exact="Acute" post="heart failure and cardiogenic shock In a series of"/>
  <result pre="treated in the same way as in non-COVID patients.3 Acute" exact="heart" post="failure and cardiogenic shock In a series of 191"/>
  <result pre="same way as in non-COVID patients.3 Acute heart failure and" exact="cardiogenic shock" post="In a series of 191 patients with COVID-19, acute"/>
  <result pre="cardiogenic shock In a series of 191 patients with COVID-19," exact="acute" post="heart failure occurred in 44 patients (23%). The incidence"/>
  <result pre="shock In a series of 191 patients with COVID-19, acute" exact="heart" post="failure occurred in 44 patients (23%). The incidence was"/>
  <result pre="compared with those who survived (52% versus 21%, pÂ 23" exact="Acute" post="heart failure and cardiogenic shock in COVID-19 cases can"/>
  <result pre="with those who survived (52% versus 21%, pÂ 23 Acute" exact="heart" post="failure and cardiogenic shock in COVID-19 cases can occur"/>
  <result pre="survived (52% versus 21%, pÂ 23 Acute heart failure and" exact="cardiogenic shock" post="in COVID-19 cases can occur secondary to exacerbation of"/>
  <result pre="heart failure and cardiogenic shock in COVID-19 cases can occur" exact="secondary" post="to exacerbation of pre-existing left ventricular dysfunction, and/or due"/>
  <result pre="COVID-19 cases can occur secondary to exacerbation of pre-existing left" exact="ventricular dysfunction," post="and/or due to new onset myocarditis, ACS, cardiac arrhythmias,"/>
  <result pre="myocarditis, ACS, cardiac arrhythmias, and stress-induced cardiomyopathy. Possibility of right" exact="heart" post="failure and associated pulmonary HTN should always be kept"/>
  <result pre="and stress-induced cardiomyopathy. Possibility of right heart failure and associated" exact="pulmonary" post="HTN should always be kept in view of severe"/>
  <result pre="HTN should always be kept in view of severe parenchymal" exact="lung disease" post="and ARDS. Coronary CT angiogram and echocardiography are valuable"/>
  <result pre="should always be kept in view of severe parenchymal lung" exact="disease" post="and ARDS. Coronary CT angiogram and echocardiography are valuable"/>
  <result pre="risk of arterial and VTEÂ because of a state of" exact="vascular" post="inflammation, endothelial dysfunction, and hypercoagulability associated with COVID-19 infection.3,30"/>
  <result pre="and fibrin degradation productsÂ levels, and a higher incidence of" exact="disseminated intravascular coagulation," post="among non-surviving patients, compared with survivors.3,31 However, there is"/>
  <result pre="coagulation, among non-surviving patients, compared with survivors.3,31 However, there is" exact="limited" post="data on the incidence of thrombotic complications associated with"/>
  <result pre="venous and 4% arterial) despite receiving standard doses of thromboprophylaxis.30" exact="Pulmonary" post="embolism was the most frequent thrombotic complication.30 Thromboprophylaxis is"/>
  <result pre="patient with COVID-19 demonstrates sudden clinical deterioration as evidenced by" exact="hypoxia" post="or hemodynamic instability, the thromboembolic disease should always be"/>
  <result pre="deterioration as evidenced by hypoxia or hemodynamic instability, the thromboembolic" exact="disease" post="should always be considered in the differential diagnosis with"/>
  <result pre="with a low threshold for using the appropriate diagnostic tests." exact="Acute coronary syndrome" post="As aforementioned, COVID-19 induces a state of the infection-induced"/>
  <result pre="low threshold for using the appropriate diagnostic tests. Acute coronary" exact="syndrome" post="As aforementioned, COVID-19 induces a state of the infection-induced"/>
  <result pre="pandemic began.33, 34, 35 These decreased numbers are more likely" exact="secondary" post="to people preferring to stay at home in the"/>
  <result pre="with the monthly average of the previous year.34 Extensive infarctions," exact="heart" post="failure, high coronary thrombus burden, and no reflow were"/>
  <result pre="Similarly, delays in presentation and management of patients with ST-elevation" exact="myocardial infarction" post="were recorded in a small observational study in Hongkong,"/>
  <result pre="health-care system with patients with COVID-19 and fear of contracting" exact="infection" post="among patients. There is no apparent reason for a"/>
  <result pre="mimicking conditions.37,38 There is an ever-increasing recognition of COVID-19 associated" exact="myocarditis" post="simulating an ST-elevation myocardial infarction presentation, and also of"/>
  <result pre="an ever-increasing recognition of COVID-19 associated myocarditis simulating an ST-elevation" exact="myocardial infarction" post="presentation, and also of the frequent rise of troponin"/>
  <result pre="appropriate therapy. Prognostic implications of cardiac injury associated with COVID-19" exact="Acute" post="myocardial injury (reflected by elevated cardiac enzymes secondary to"/>
  <result pre="with COVID-19 Acute myocardial injury (reflected by elevated cardiac enzymes" exact="secondary" post="to ischemic/non-ischemic etiology, and also the electrocardiographic and echocardiographic"/>
  <result pre="in patients with COVID-19 and is associated with more severe" exact="disease" post="and worse prognosis.3,13,20 In a study involving 416 patients"/>
  <result pre="all these evidence reaffirm that patients with COVID-19 who develop" exact="acute" post="myocardial injury have a high risk of major complications"/>
  <result pre="patients with prior CVD. Considerations for prevention and treatment of" exact="cardiovascular" post="complications India, as on 25th April 2020, is witnessing"/>
  <result pre="of hospitalized patients and, as aforementioned, a high burden of" exact="cardiovascular" post="complications. The hospital systems need to ensure preparedness for"/>
  <result pre="such patients, many of whom would need ICU care and/or" exact="acute" post="cardiac care. Unfortunately, no specific antiviral therapy or vaccines"/>
  <result pre="or vaccines are available for COVID-19. Preventive measures, along with" exact="symptomatic" post="supportive treatment, are the best strategies for COVID-19 and"/>
  <result pre="CVD, or its risk factors are more prone to develop" exact="cardiovascular" post="morbidity and mortality. Hence, appropriate protocols for rapid diagnosis,"/>
  <result pre="diagnosis, triaging, isolation, and treatment of patients with COVID-19 with" exact="cardiovascular" post="complications should be prepared and well-rehearsed by the hospital"/>
  <result pre="be prepared and well-rehearsed by the hospital administration. As a" exact="cardiovascular" post="physician, it is imperative to encourage the use of"/>
  <result pre="for optimal use of personal protective equipment (PPE) is recommended." exact="American" post="College of Cardiology, in a recent statement, has recommended"/>
  <result pre="natriuretic peptides in patients with COVID-19 unless the diagnosis of" exact="acute" post="MI or heart failure is suspected on clinical grounds.39"/>
  <result pre="patients with COVID-19 unless the diagnosis of acute MI or" exact="heart" post="failure is suspected on clinical grounds.39 However, there is"/>
  <result pre="towardÂ death. In contrast, the levels of these biomarkers remain" exact="stable" post="and low in those with less severe disease and"/>
  <result pre="biomarkers remain stable and low in those with less severe" exact="disease" post="and a more favorable clinical course towardÂ successful treatment"/>
  <result pre="clinical course towardÂ successful treatment and discharge.20 Therefore, frequent and" exact="periodic" post="estimation of cardiac biomarkers such as troponin, and NT-pro"/>
  <result pre="induced by therapy with ACE-I or ARB would aggravate the" exact="infection" post="with SARS-CoV-2. However, the available data does not show"/>
  <result pre="a beneficial effect of ACE-I/ARB therapy in patients hospitalized with" exact="viral" post="pneumonia.40 The mechanism responsible for this beneficial effect was"/>
  <result pre="responsible for this beneficial effect was a reduction in the" exact="viral" post="infectionâ€&quot;induced pulmonary inflammatory response and cytokine release. Some have"/>
  <result pre="this beneficial effect was a reduction in the viral infectionâ€&quot;induced" exact="pulmonary" post="inflammatory response and cytokine release. Some have attributed this"/>
  <result pre="are associated with increased mortality. Elevation of cardiac enzymes, suggesting" exact="acute" post="cardiac injury, can occur in up to one-fourth of"/>
  <result pre="predict prognosis. Our understanding of this novel coronavirus and its" exact="cardiovascular" post="implications is still evolving. Researchers around the world need"/>
  <result pre="1WangD.HuB.HuC.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA32320201061106910.1001/jama.2020.1585 2HuangC.WangY.LiX.Clinical features of patients infected with"/>
  <result pre="patients, health care workers, and health systems during the coronavirus" exact="disease" post="2019 (COVID-19) pandemicJ Am Coll Cardiol2020 Mar 1810.1016/j.jacc.2020.03.031pii: S0735-1097(20)34637-4"/>
  <result pre="2020 (J)China CDC Weekly22020113122 6MadjidM.Safavi-NaeiniP.SolomonS.D.Potential effects of coronaviruses on the" exact="cardiovascular" post="system: a reviewJAMA Cardiol2020 Mar 2710.1001/jamacardio.2020.1286 7TikellisC.ThomasM.C.Angiotensin-converting enzyme 2"/>
  <result pre="of the renin-angiotensin system be withdrawn in patients with COVID-19?Eur" exact="Heart" post="J2020 Mar 2010.1093/eurheartj/ehaa235pii: ehaa235 9ChanJ.W.M.NgC.K.ChanY.H.Short term outcome and risk"/>
  <result pre="risk factors for adverse clinical outcomes in adults with severe" exact="acute" post="respiratory syndrome (SARS)Thorax58200368668912885985 10BoothC.M.MatukasL.M.TomlinsonG.A.Clinical features and short-term outcomes of"/>
  <result pre="factors for adverse clinical outcomes in adults with severe acute" exact="respiratory" post="syndrome (SARS)Thorax58200368668912885985 10BoothC.M.MatukasL.M.TomlinsonG.A.Clinical features and short-term outcomes of 144"/>
  <result pre="for adverse clinical outcomes in adults with severe acute respiratory" exact="syndrome" post="(SARS)Thorax58200368668912885985 10BoothC.M.MatukasL.M.TomlinsonG.A.Clinical features and short-term outcomes of 144 patients"/>
  <result pre="greater Toronto areaJama28920032801280912734147 11BadawiA.RyooS.G.Prevalence of comorbidities in the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): a systematic review and meta-analysisInt J"/>
  <result pre="Toronto areaJama28920032801280912734147 11BadawiA.RyooS.G.Prevalence of comorbidities in the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): a systematic review and meta-analysisInt J Infect"/>
  <result pre="review and meta-analysisInt J Infect Dis49201612913310.1016/j.ijid.2016.06.01527352628 12GuanW.J.NiZ.Y.HuY.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med2020 Feb 2810.1056/NEJMoa2002032 13ShiS.QinM.ShenB.Association"/>
  <result pre="J Infect Dis2020 Mar 1210.1016/j.ijid.2020.03.017pii: S1201-9712(20)30136-3 15LiB.YangJ.ZhaoF.Prevalence and impact of" exact="cardiovascular" post="metabolic diseases on COVID-19 in ChinaClin Res Cardiol2020 Mar"/>
  <result pre="Infect Dis2020 Mar 1210.1016/j.ijid.2020.03.017pii: S1201-9712(20)30136-3 15LiB.YangJ.ZhaoF.Prevalence and impact of cardiovascular" exact="metabolic diseases" post="on COVID-19 in ChinaClin Res Cardiol2020 Mar 1110.1007/s00392-020-01626-9 16OnderG.RezzaG.BrusaferroS.Case-fatality"/>
  <result pre="prevalence of selected underlying health conditions among patients with coronavirus" exact="disease" post="2019 â€&quot; United States, february 12â€&quot;march 28, 2020MMWR Morb"/>
  <result pre="States, february 12â€&quot;march 28, 2020MMWR Morb Mortal Wkly Rep69202038238632240123 18lhogbaniT.Acute" exact="myocarditis" post="associated with novel Middle East respiratory syndrome coronavirusAnn Saudi"/>
  <result pre="Mortal Wkly Rep69202038238632240123 18lhogbaniT.Acute myocarditis associated with novel Middle East" exact="respiratory" post="syndrome coronavirusAnn Saudi Med362016788026922692 19WuQ.ZhouL.SunX.Altered lipid metabolism in recovered"/>
  <result pre="Wkly Rep69202038238632240123 18lhogbaniT.Acute myocarditis associated with novel Middle East respiratory" exact="syndrome" post="coronavirusAnn Saudi Med362016788026922692 19WuQ.ZhouL.SunX.Altered lipid metabolism in recovered SARS"/>
  <result pre="22911010.1038/s41598-017-09536-z28831119 20GuoT.FanY.ChenM.Cardiovascular implications of fatal outcomes of patients with coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol27202010.1001/jamacardio.2020.1017Published online March 21RaliA.S.SauerA.J.COVID-19 pandemic and cardiovascular"/>
  <result pre="coronavirus disease 2019 (COVID-19)JAMA Cardiol27202010.1001/jamacardio.2020.1017Published online March 21RaliA.S.SauerA.J.COVID-19 pandemic and" exact="cardiovascular" post="diseaseUS Cardiol142020e01 22LippiG.LavieC.J.Sanchis-GomarF.Cardiac troponin I in patients with coronavirus"/>
  <result pre="cardiovascular diseaseUS Cardiol142020e01 22LippiG.LavieC.J.Sanchis-GomarF.Cardiac troponin I in patients with coronavirus" exact="disease" post="2019 (COVID-19): evidence from a meta-analysisProg Cardiovasc Dis2020 23ZhouF.YuT.DuR.Clinical"/>
  <result pre="Cardiovasc Dis2020 23ZhouF.YuT.DuR.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="in Wuhan, China: a retrospective cohort studyLancet202010.1016/S0140-6736(20)30566-3PMID: 32171076 24HuH.MaF.WeiX.Coronavirus fulminant" exact="myocarditis" post="saved with glucocorticoid and human immunoglobulinEur Heart J. March16202010.1093/eurheartj/ehaa190[epub"/>
  <result pre="32171076 24HuH.MaF.WeiX.Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulinEur" exact="Heart" post="J. March16202010.1093/eurheartj/ehaa190[epub ahead of print] 25InciardiR.M.LupiL.ZacconeG.Cardiac involvement in a"/>
  <result pre="ahead of print] 25InciardiR.M.LupiL.ZacconeG.Cardiac involvement in a patient with coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol27202010.1001/jamacardio.2020.1096Published online March 26SalaS.PerettoG.GramegnaM.Acute myocarditis presenting as"/>
  <result pre="patient with coronavirus disease 2019 (COVID-19)JAMA Cardiol27202010.1001/jamacardio.2020.1096Published online March 26SalaS.PerettoG.GramegnaM.Acute" exact="myocarditis" post="presenting as a reverse Tako-Tsubo syndrome in a patient"/>
  <result pre="Cardiol27202010.1001/jamacardio.2020.1096Published online March 26SalaS.PerettoG.GramegnaM.Acute myocarditis presenting as a reverse Tako-Tsubo" exact="syndrome" post="in a patient with SARS-CoV-2 respiratory infection [published online"/>
  <result pre="as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2" exact="respiratory" post="infection [published online ahead of print, 2020 Apr 8]Eur"/>
  <result pre="a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory" exact="infection" post="[published online ahead of print, 2020 Apr 8]Eur Heart"/>
  <result pre="respiratory infection [published online ahead of print, 2020 Apr 8]Eur" exact="Heart" post="J202010.1093/eurheartj/ehaa286ehaa286 27LiuK.FangY.Y.DengY.Clinical characteristics of novel coronavirus cases in tertiary"/>
  <result pre="hospitals in Hubei ProvinceChin Med J (Engl)2020 28WuC.-I.PostemaP.G.ArbeloE.SARS-CoV-2, COVID-19 and" exact="Inherited" post="Arrhythmia Syndromes2020Heart Rhythm10.1016/j.hrthm.2020.03.024 29HuiH.ZhangY.YangX.Clinical and radiographic features of cardiac"/>
  <result pre="in Hubei ProvinceChin Med J (Engl)2020 28WuC.-I.PostemaP.G.ArbeloE.SARS-CoV-2, COVID-19 and Inherited" exact="Arrhythmia" post="Syndromes2020Heart Rhythm10.1016/j.hrthm.2020.03.024 29HuiH.ZhangY.YangX.Clinical and radiographic features of cardiac injury"/>
  <result pre="ahead of print, 2020 Apr 21]. Circulation, 10.1161/CIRCULATIONAHA.120.047523 35MetzlerB.SiostrzonekP.BinderR.K.BauerA.ReinstadlerS.J.Decline of" exact="acute" post="coronary syndrome admissions in Austria since the outbreak of"/>
  <result pre="print, 2020 Apr 21]. Circulation, 10.1161/CIRCULATIONAHA.120.047523 35MetzlerB.SiostrzonekP.BinderR.K.BauerA.ReinstadlerS.J.Decline of acute coronary" exact="syndrome" post="admissions in Austria since the outbreak of COVID-19: the"/>
  <result pre="collateral damage [published online ahead of print, 2020 Apr 16]Eur" exact="Heart" post="J2020ehaa314 36TamC.F.CheungK.S.LamS.Impact of coronavirus disease 2019 (COVID-19) outbreak on"/>
  <result pre="of print, 2020 Apr 16]Eur Heart J2020ehaa314 36TamC.F.CheungK.S.LamS.Impact of coronavirus" exact="disease" post="2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in"/>
  <result pre="J2020ehaa314 36TamC.F.CheungK.S.LamS.Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation" exact="myocardial infarction" post="care in Hong Kong, ChinaCirc Cardiovasc Qual Outcomes132020e00663110.1161/CIRCOUTCOMES.120.006631 37MahmudE.DauermanH.L.WeltF.G.Management"/>
  <result pre="care in Hong Kong, ChinaCirc Cardiovasc Qual Outcomes132020e00663110.1161/CIRCOUTCOMES.120.006631 37MahmudE.DauermanH.L.WeltF.G.Management of" exact="Acute" post="Myocardial Infarction during the COVID-19 PandemicCathet Cardiovasc Interv202010.1002/ccd.28946[published online"/>
  <result pre="Hong Kong, ChinaCirc Cardiovasc Qual Outcomes132020e00663110.1161/CIRCOUTCOMES.120.006631 37MahmudE.DauermanH.L.WeltF.G.Management of Acute Myocardial" exact="Infarction" post="during the COVID-19 PandemicCathet Cardiovasc Interv202010.1002/ccd.28946[published online ahead of"/>
  <result pre="2020. 40HenryC.ZaizafounM.StockE.Impact of angiotensin- converting enzyme inhibitors and statins on" exact="viral" post="pneumoniaSAVE Proc31201841942310.1080/08998280.2018.1499293 41KubaK.ImaiY.RaoS.A crucial role of angiotensin converting enzyme"/>
  <result pre="enzyme 2 (ACE2) in SARS coronavirus-induced lung injuryNat Med11200587587910.1038/nm126716007097 42BavishiC.MaddoxT.M.MesserliF.H.Coronavirus" exact="disease" post="2019 (COVID-19) infection and renin angiotensin system BlockersJAMA Cardiol202010.1001/jamacardio.2020.1282Published"/>
  <result pre="in SARS coronavirus-induced lung injuryNat Med11200587587910.1038/nm126716007097 42BavishiC.MaddoxT.M.MesserliF.H.Coronavirus disease 2019 (COVID-19)" exact="infection" post="and renin angiotensin system BlockersJAMA Cardiol202010.1001/jamacardio.2020.1282Published online April 03"/>
  <result pre="the coronavirus (COVID 19) pandemic: a joint statement from the" exact="American" post="College of Cardiology (acc) interventional council and the society"/>
  <result pre="College of Cardiology (acc) interventional council and the society of" exact="cardiovascular" post="angiography and intervention (scai)J Am Coll Cardiol2020 Mar 1610.1016/j.jacc.2020.03.021pii:"/>
 </snippets>
</snippetsTree>
